Effect of aerosolized surfactant in patients with stable chronic bronchitis

A prospective randomized controlled trial

Antonio Anzueto, Amal Jubran, Jill A. Ohar, Craig Arnold Piquette, Stephen I. Rennard, Gene Colice, Edward N. Pattishall, Janet Barrett, Melissa Engle, Kenneth A. Perret, Bruce K. Rubin

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Context. - Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective. - To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design. - A prospective, multicenter, randomized, double-blind, parallel- group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting. - Four US teaching hospitals. Participants. - A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures. - Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results. - A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline. In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1- improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion. - Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.

Original languageEnglish (US)
Pages (from-to)1426-1431
Number of pages6
JournalJournal of the American Medical Association
Volume278
Issue number17
DOIs
StatePublished - Nov 5 1997

Fingerprint

Chronic Bronchitis
Surface-Active Agents
Randomized Controlled Trials
Sputum
Cilia
Forced Expiratory Volume
Therapeutics
Placebos
Total Lung Capacity
Pulmonary Surfactants
Adhesiveness
Lung
Residual Volume
Mucus
Teaching Hospitals
Thorax
Gases
Demography
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of aerosolized surfactant in patients with stable chronic bronchitis : A prospective randomized controlled trial. / Anzueto, Antonio; Jubran, Amal; Ohar, Jill A.; Piquette, Craig Arnold; Rennard, Stephen I.; Colice, Gene; Pattishall, Edward N.; Barrett, Janet; Engle, Melissa; Perret, Kenneth A.; Rubin, Bruce K.

In: Journal of the American Medical Association, Vol. 278, No. 17, 05.11.1997, p. 1426-1431.

Research output: Contribution to journalArticle

Anzueto, A, Jubran, A, Ohar, JA, Piquette, CA, Rennard, SI, Colice, G, Pattishall, EN, Barrett, J, Engle, M, Perret, KA & Rubin, BK 1997, 'Effect of aerosolized surfactant in patients with stable chronic bronchitis: A prospective randomized controlled trial', Journal of the American Medical Association, vol. 278, no. 17, pp. 1426-1431. https://doi.org/10.1001/jama.278.17.1426
Anzueto, Antonio ; Jubran, Amal ; Ohar, Jill A. ; Piquette, Craig Arnold ; Rennard, Stephen I. ; Colice, Gene ; Pattishall, Edward N. ; Barrett, Janet ; Engle, Melissa ; Perret, Kenneth A. ; Rubin, Bruce K. / Effect of aerosolized surfactant in patients with stable chronic bronchitis : A prospective randomized controlled trial. In: Journal of the American Medical Association. 1997 ; Vol. 278, No. 17. pp. 1426-1431.
@article{e470c5b969364441924adb3c9bfeda78,
title = "Effect of aerosolized surfactant in patients with stable chronic bronchitis: A prospective randomized controlled trial",
abstract = "Context. - Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective. - To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design. - A prospective, multicenter, randomized, double-blind, parallel- group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting. - Four US teaching hospitals. Participants. - A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures. - Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results. - A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline. In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4{\%}; postbronchodilator FEV1- improved 10.4{\%} by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2{\%} by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion. - Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.",
author = "Antonio Anzueto and Amal Jubran and Ohar, {Jill A.} and Piquette, {Craig Arnold} and Rennard, {Stephen I.} and Gene Colice and Pattishall, {Edward N.} and Janet Barrett and Melissa Engle and Perret, {Kenneth A.} and Rubin, {Bruce K.}",
year = "1997",
month = "11",
day = "5",
doi = "10.1001/jama.278.17.1426",
language = "English (US)",
volume = "278",
pages = "1426--1431",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "17",

}

TY - JOUR

T1 - Effect of aerosolized surfactant in patients with stable chronic bronchitis

T2 - A prospective randomized controlled trial

AU - Anzueto, Antonio

AU - Jubran, Amal

AU - Ohar, Jill A.

AU - Piquette, Craig Arnold

AU - Rennard, Stephen I.

AU - Colice, Gene

AU - Pattishall, Edward N.

AU - Barrett, Janet

AU - Engle, Melissa

AU - Perret, Kenneth A.

AU - Rubin, Bruce K.

PY - 1997/11/5

Y1 - 1997/11/5

N2 - Context. - Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective. - To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design. - A prospective, multicenter, randomized, double-blind, parallel- group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting. - Four US teaching hospitals. Participants. - A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures. - Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results. - A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline. In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1- improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion. - Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.

AB - Context. - Chronic bronchitis, estimated to affect more than 13 million adults in the United States, is characterized in part by retention of airway secretions, but no approved or effective therapy for airway mucus retention in patients with chronic bronchitis has been established. Surfactant reduces sputum adhesiveness, which contributes to difficulty in clearing secretions, but surfactant has not been tested in patients with chronic bronchitis. Objective. - To examine the effects of exogenous surfactant on sputum clearance and pulmonary function in patients with stable chronic bronchitis. Design. - A prospective, multicenter, randomized, double-blind, parallel- group, placebo-controlled comparison of the effects of 2 weeks of treatment with 3 doses of aerosolized surfactant (palmitoylphosphadidylcholine [DPPC]) or saline (placebo). Setting. - Four US teaching hospitals. Participants. - A total of 87 adult patients with the diagnosis of stable chronic bronchitis. Main Outcome Measures. - Pulmonary function, respiratory symptoms, and sputum properties before treatment (day 0), after 2 weeks of treatment (day 14), and 7 days after stopping treatment (day 21). Results. - A total of 66 patients were randomized to surfactant treatment and 21 to saline treatment. Patient demographic characteristics between groups were similar at baseline. In patients who received a DPPC dose of 607.5 mg/d for 2 weeks, prebronchodilator forced expiratory volume in 1 second (FEV1) increased from 1.22 L (SEM, 0.08 L) at day 0 to 1.33 L (SEM, 0.09 L) at day 21 (P=.05), an improvement of 11.4%; postbronchodilator FEV1- improved 10.4% by days 14 and 21 (P=.02); and the ratio of residual volume to total lung capacity, a measure of thoracic gas trapping, decreased 6.2% by day 21 (P=.009). In the surfactant groups, there was a dose-dependent increase in the ability of sputum to be transported by cilia in vitro. Conclusion. - Aerosolized surfactant improved pulmonary function and resulted in a dose-related improvement in sputum transport by cilia in patients with stable chronic bronchitis.

UR - http://www.scopus.com/inward/record.url?scp=0030611938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030611938&partnerID=8YFLogxK

U2 - 10.1001/jama.278.17.1426

DO - 10.1001/jama.278.17.1426

M3 - Article

VL - 278

SP - 1426

EP - 1431

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 17

ER -